Fabry disease
Stories
-
BioMarin enters exclusive worldwide license for investigational Fabry therapy
BioMarin will make an upfront payment of $70 million for HM15421/GC1134A and may receive up to $405 million in milestone payments. The company will assume sole responsibility for all subsequent clinical development, manufacturing and commercialization outside of Korea.